Skip to main content
. Author manuscript; available in PMC: 2021 Apr 22.
Published in final edited form as: Chem Rev. 2020 Mar 23;120(8):3787–3851. doi: 10.1021/acs.chemrev.9b00738

Table 2.

Representative Clinical-Stage ImmunoPET Imaging Probesa

probe target targeting moiety cancer types ref
89Zr-Df-cetuximab EGFR mAb solid tumors 356,358
89Zr-panitumumab EGFR mAb colorectal cancer 368
89Zr-Df-trastuzumab HER2 mAb breast cancer, EGA 41,391,399
64Cu-DOTA-trastuzumab HER2 mAb breast cancer 394,395
89Zr-Df-pertuzumab HER2 mAb breast cancer 396
124I-trastuzumab HER2 mAb GC, GEC 400
68Ga-HER2-Nanobody HER2 Nanobody breast cancer 412
68Ga-ABY-025 HER2 Affibody breast cancer 430,433
64Cu-DOTA-patritumab HER3 mAb solid tumors 453
89Zr-GSK2849330 HER3 mAb solid tumors 455
89Zr-lumretuzumab HER3 mAb solid tumors 458
89Zr-Df-bevacizumab VEGF mAb solid tumors 469,471,474
124I-huA33 A33 mAb colorectal cancer 185
89Zr-cmAb U36 CD44v6 mAb HNSCC 118
89Zr-RG7356 CD44 mAb solid tumors 523,524
89Zr-rituximab CD20 mAb lymphoma 536
89Zr-DFO-5B1 CA19.9 mAb pancreatic cancer 39
89Zr-huJ591 PSMA mAb prostate cancer 619,620
89Zr-Df-IAB2M PSMA Mb prostate cancer 633,634
68Ga-IMP288 CEA BsAb medullary thyroid cancer 654
89Zr-AMG 211 CEA/CD3 BiTE gastrointestinal adenocarcinomas 664
89Zr-CEA-IL2 CEA immunocytokine solid tumors
89Zr-girentuximab CAIX mAb renal cell carcinoma 674
124I-cG250 CAIX mAb renal cell carcinoma 675
89Zr-DF0-MSTP2109A STEAP1 mAb prostate cancer 748,749
89Zr-fresolimumab TGF-β mAb glioma 754
89Zr-Df-IAB22M2C CD8 Mb solid tumors 793
89Zr-atezolizumab PD-L1 mAb NSCLC, TNBC, bladder cancer 21
18F-BMS-986192 PD-L1 adnectin lung cancer 809
89Zr-nivolumab PD1 mAb lung cancer 809
[124I]I-F8-IL10 fibronectin Fv fragment rheumatoid arthritis 843
a

Abbreviations: mAb, monoclonal antibody; EGA, esophagogastric adenocarcinoma; GC, gastric cancer; GEC, gastroesophageal junction cancer; HNSCC, squamous cell carcinoma of the head and neck; Mb, minibody; Fv fragment, single-chain antibody variable domain (Fv) fragment; BsAb, bispecific antibody; BiTE, bispecific T-cell engager; PSMA, prostate-specific membrane antigen; CEA, carcinoembryonic antigen; CAIX, carbonic anhydrase IX; STEAP1, six-transmembrane epithelial antigen of prostate-1; TGF-β, transforming growth factor-β; NSCLC, nonsmall cell lung cancer; TNBC, triple-negative breast cancer; PD-L1, programmed death ligand-1; PD1, programmed death receptor 1.